<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on February 03, 2023</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00461344</url>
  </required_header>
  <id_info>
    <org_study_id>XRP6976D_2504</org_study_id>
    <nct_id>NCT00461344</nct_id>
  </id_info>
  <brief_title>Docetaxel + Doxorubicin as Neoadjuvant Chemotherapy in Patients With Breast Cancer</brief_title>
  <official_title>A Multicenter, Open Label, Phase II Trial Evaluating Docetaxel + Anthracycline x 4 Cycles Followed by Docetaxel Single Agent x 4 Cycles as First-Line Therapy in Patients With Her2 Negative Locally Advanced or Metastatic Breast Cancer Who Have Relapsed ≥ 12 Months From Completion of Neoadjuvant/Adjuvant Taxotere®- Based Chemotherapy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sanofi</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Sanofi</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Primary: To determine the pathological remission following the chemotherapy combination&#xD;
      docetaxel and doxorubicin in large breast cancer&#xD;
&#xD;
      Secondary:&#xD;
&#xD;
        -  Clinical response rate&#xD;
&#xD;
        -  To investigate the safety of docetaxel doxorubicin combination in the treatment for&#xD;
           neoadjuvant chemotherapy of breast cancer&#xD;
&#xD;
        -  Type of surgery (radical/conservative)&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    due to slow recruitment of patients&#xD;
  </why_stopped>
  <start_date>July 2004</start_date>
  <completion_date type="Actual">August 2007</completion_date>
  <primary_completion_date type="Actual">June 2005</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Primary 1. to determine the pathological remission following the chemotherapy combination docetaxel and doxorubicin in large breast cancer</measure>
  </primary_outcome>
  <secondary_outcome>
    <measure>Secondary: 1. Clinical response rate 2. to investigate the safety of docetaxel doxorubicin combination in the treatment for neoadjuvant chemotherapy of breast cancer 3. Type of surgery (radical/conservative)</measure>
  </secondary_outcome>
  <enrollment type="Actual">20</enrollment>
  <condition>Ductal Carcinoma</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Docetaxel</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Doxorubicin</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Histologically verified breast cancer&#xD;
&#xD;
          -  Large (≥ 3 cm) breast cancer&#xD;
&#xD;
          -  IIb-IIIa stage&#xD;
&#xD;
          -  ECOG (Eastern Cooperative Oncology Group) status: 0-1-2&#xD;
&#xD;
          -  Adequate bone marrow reserve: (Haemoglobin ≥ 12g/l, Absolute Neutrophil Count (ANC) ≥&#xD;
             2.0x 10^9, Platelets ≥100 000)&#xD;
&#xD;
          -  Laboratory results:&#xD;
&#xD;
          -  Bilirubin ≤ Upper Limit Normal (ULN)&#xD;
&#xD;
          -  Serum Glutamate Pyruvate Transaminase (SGPT) ≤ 2.5 ULN, Serum Glutamate Oxaloacetate&#xD;
             Transaminase (SGOT) ≤ 2.5 ULN,&#xD;
&#xD;
          -  Alk.phosph. ≤ 5.0 ULN,&#xD;
&#xD;
          -  Creatinin ≤ ULN, if borderline calculated at ≤ 60ml/min&#xD;
&#xD;
          -  Normal cardiac function (the result of Left Ventricular Ejection Function (LVEF) must&#xD;
             be above the lower limit of normal for the institution)&#xD;
&#xD;
          -  Negative pregnancy test&#xD;
&#xD;
          -  Hormonal receptor status assessed&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Pregnancy or lactation&#xD;
&#xD;
          -  SGOT and/or SGPT &gt; 1.5 upper limit normal, associated with Alk.phosph &gt; 2.5 ULN&#xD;
&#xD;
          -  Serious medical condition including but not limited to:&#xD;
&#xD;
          -  Uncontrolled hypertension&#xD;
&#xD;
          -  Active ulcus pepticum&#xD;
&#xD;
          -  Non-stable diabetes mellitus&#xD;
&#xD;
          -  Other contraindication of steroid treatment&#xD;
&#xD;
          -  Myocardial infarction within the last 6 months prior study entry&#xD;
&#xD;
          -  Significant neurologic/psychiatric disorders&#xD;
&#xD;
          -  Active infection&#xD;
&#xD;
          -  Peripheral neuropathy grade ≥ 2&#xD;
&#xD;
          -  Unstable angina&#xD;
&#xD;
          -  Severe arrhythmia&#xD;
&#xD;
          -  Participation in other clinical trial&#xD;
&#xD;
          -  Prior surgery, chemotherapy, hormonotherapy for breast cancer&#xD;
&#xD;
          -  Past or current history of neoplasm other than breast cancer, except for: curatively&#xD;
             treated non-melanoma skin cancer, in situ carcinoma of the cervix, other cancer&#xD;
             curatively treated and with no evidence of disease for at least 7 years&#xD;
&#xD;
          -  History of hypersensitivity to the investigational products or to drugs with similar&#xD;
             chemical structures&#xD;
&#xD;
          -  Likelihood of requiring treatment during the study period with drugs not permitted by&#xD;
             the clinical study protocol&#xD;
&#xD;
          -  Treatment with any investigational product in the last 1 month before study entry.&#xD;
&#xD;
        The above information is not intended to contain all considerations relevant to a patient's&#xD;
        potential participation in a clinical trial.&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>László Erős</last_name>
    <role>Study Director</role>
    <affiliation>sanofi-aventis Hungary</affiliation>
  </overall_official>
  <verification_date>April 2008</verification_date>
  <study_first_submitted>April 17, 2007</study_first_submitted>
  <study_first_submitted_qc>April 17, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 18, 2007</study_first_posted>
  <last_update_submitted>April 1, 2008</last_update_submitted>
  <last_update_submitted_qc>April 1, 2008</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 3, 2008</last_update_posted>
  <keyword>Breast</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma, Ductal</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Docetaxel</mesh_term>
    <mesh_term>Doxorubicin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

